No Data
No Data
Jenscare Scientific: Pan Fei Appointed as CEO
Jianshi Technology-B (09877.HK) has appointed Pan Fei as the Chief Executive Officer.
Gelonghui, January 15 | Health Technology-B (09877.HK) announced that to further promote the Group's Global Strategy and comprehensively deepen and accelerate the Global commercialization process, Mr. Lu Shiwun has informed the company that he will resign from the position of Chief Executive Officer and has nominated Mr. Pan Fei as the Chief Executive Officer. The appointment of the Chief Executive Officer has been unanimously approved by the company's nomination committee and Board of Directors on January 15, 2025.
Express News | Jenscare Scientific Co Ltd - Lv Shiwen Shall Resign as Chief Executive Officer
While Institutions Invested in Jenscare Scientific Co., Ltd. (HKG:9877) Benefited From Last Week's 31% Gain, Individual Investors Stood to Gain the Most
The One-Year Outcome of LuX-Valve Plus TRAVEL II Study Was Officially Released at TCT 2024
Genex Technology-B(09877.HK): LuX-Valve Plus TRAVEL II one-year clinical follow-up results will be released at the 2024 Washington conference of the American College of Cardiology.
GloryOct31NewsFlash HealthTech-B (09877.HK) announced that recently, the one-year clinical follow-up results of the LuX-Valve Plus vascular tricuspid valve intervention replacement system multicenter clinical trial (TRAVEL II) were unveiled at the 2024 Transcatheter Cardiovascular Therapeutics Conference (TCT 2024) in the USA. TRAVEL II is mainly used to evaluate the long-term safety and effectiveness of LuX-Valve Plus in patients with severe tricuspid valve regurgitation. The TRAVEL II clinical trial included a total of 96 patients from 15 centers in China.